ArmaGen is a privately held biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Our lead product candidates, AGT-182 for Hunter syndrome and AGT-181 for Hurler syndrome, are both funded. ArmaGen expects to initiate a Phase 1 clinical trial for AGT-182 in the first quarter of 2015, and AGT-181 is poised to enter early-stage clinical trials in 2015.
ArmaGen closed a $17 million series A financing in 2012 led by a consortium of top biopharmaceutical investment firms. The investor group is led by the Boehringer Ingelheim Venture Fund GmbH, and includes Shire plc, Takeda Ventures, Inc. and Mitsui Corporation Venture Partnership Technology Fund I, LLC.
Corporate Fact Sheet